{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:02Z","timestamp":1789560122730,"version":"build-2803163510"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"name":"National Cancer Institute","award":["UG1 CA23330"],"award-info":[{"award-number":["UG1 CA23330"]}]},{"name":"National Cancer Institute","award":["P50 CA098252"],"award-info":[{"award-number":["P50 CA098252"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Despite effective screening strategies and the development and implementation of prophylactic high-risk human papillomavirus vaccination, cervical cancer remains a significant public health burden. This burden is most pronounced in under-resourced countries without fully developed screening and vaccination programs, although the disease remains present worldwide, including in industrialized countries. To that end, the World Health Organization (WHO) has an active focus on the elimination of cervical cancer, with objective metrics to be achieved by countries by the year 2030. Although increased vaccination and screening will be needed to approach potential eradication of cervical cancer, as recognized by the WHO initiative, treatment will need to continue to not only be effective in the near term, but to improve outcomes as well. Accordingly, assessments to improve primary treatment options, including surgery for women with early-stage disease, modification of chemoradiation for those with locally advanced cervical cancer, and systemic therapy for those with recurrent or metastatic presentations, are ongoing. Accordingly, we highlight important areas of both recent and ongoing focus as they relate to improving cervical cancer outcomes.<\/jats:p>","DOI":"10.1097\/aog.0000000000005413","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T17:03:48Z","timestamp":1697130228000},"page":"1322-1332","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["New Paradigms in the Treatment of Cervical Cancer"],"prefix":"10.1097","volume":"142","author":[{"given":"Teresa K. L.","family":"Boitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavonna","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ijgc-2022-003703","article-title":"Updates on cervical cancer prevention","volume":"33","author":"Viveros-Carre\u00f1o","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.pec.2017.01.020","article-title":"Predictors of adherence to follow-up recommendations after an abnormal Pap smear among underserved inner-city women","volume":"100","author":"Miller","year":"2017","journal-title":"Patient Educ Couns"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.gore.2022.101041","article-title":"Increased disparities associated with Black women and abnormal cervical cancer screening follow-up","volume":"42","author":"Boitano","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"180447","DOI":"10.5888\/pcd16.180447","article-title":"Rural-urban and racial\/ethnic disparities in invasive cervical cancer incidence in the United States, 2010-2014","volume":"16","author":"Yu","year":"2019","journal-title":"Prev Chronic Dis"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.23742","article-title":"Examining the association between socioeconomic status and potential human papillomavirus-associated cancers","volume":"113","author":"Benard","year":"2008","journal-title":"Cancer"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jnci\/91.6.506","article-title":"Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer","volume":"91","author":"Franco","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ijgo.13865","article-title":"Cancer of the cervix uteri: 2021 update","volume":"155","author":"Bhatla","year":"2021","journal-title":"Int J Gynecol Obstet"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.aogh.2014.09.014","article-title":"Screening for cancer in low- and middle-income countries","volume":"80","author":"Sankaranarayanan","year":"2014","journal-title":"Ann Glob Health"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12905-022-02043-y","article-title":"Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review","volume":"22","author":"Petersen","year":"2022","journal-title":"BMC Womens Health"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/AOG.0000000000005056","article-title":"An update on human papillomavirus vaccination in the United States","volume":"141","author":"Boitano","year":"2023","journal-title":"Obstet Gynecol"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijgo.12611","article-title":"Cancer of the cervix uteri","volume":"143","author":"Bhatla","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1804923","article-title":"Survival after minimally invasive radical hysterectomy for early-stage cervical cancer","volume":"379","author":"Melamed","year":"2018","journal-title":"N Engl J Med"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ygyno.2018.06.023","article-title":"Twenty-first century cervical cancer management: a historical perspective of the gynecologic oncology group\/NRG oncology over the past twenty years","volume":"150","author":"Leath","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","article-title":"Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Koh","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/AOG.0000000000003952","article-title":"Radical trachelectomy for the treatment of early-stage cervical cancer: a systematic review","volume":"136","author":"Smith","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.fertnstert.2020.02.003","article-title":"Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer: a systematic review","volume":"113","author":"Nezhat","year":"2020","journal-title":"Fertil Sterility"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/ijgc-2021-002921","article-title":"ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer","volume":"31","author":"Schmeler","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"R27-20260916","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003677.pub5","article-title":"Surgical approach to hysterectomy for benign gynaecological disease","author":"Aarts","year":"2015","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ejso.2015.12.014","article-title":"Robot-assisted versus open radical hysterectomy: a multi-institutional experience for early-stage cervical cancer","volume":"42","author":"Sert","year":"2016","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1186\/s12885-015-1818-4","article-title":"Laparoscopy versus laparotomy for the management of early stage cervical cancer","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMoa1806395","article-title":"Minimally invasive versus abdominal radical hysterectomy for cervical cancer","volume":"379","author":"Ramirez","year":"2018","journal-title":"N Engl J Med"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ijgc-2019-000775","article-title":"Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement","volume":"30","author":"Querleu","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2019.10.009","article-title":"GOG 244-The lymphedema and gynecologic cancer (LEG) study: incidence and risk factors in newly diagnosed patients","volume":"156","author":"Carlson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.2015-0473","article-title":"Sentinel lymph node mapping in endometrial cancer: an update","volume":"21","author":"Khoury-Collado","year":"2016","journal-title":"The Oncologist"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2017.02.005","article-title":"Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer","volume":"145","author":"Salvo","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ygyno.2021.06.018","article-title":"Sentinel lymph node mapping in early-stage cervical cancer - a national prospective multicenter study (SENTIREC trial)","volume":"162","author":"Sponholtz","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"660","DOI":"10.6004\/jnccn.2020.0027","article-title":"NCCN guidelines insights: cervical cancer, version 1.2020","volume":"18","author":"Abu-Rustum","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1200\/JCO.2004.00.0497","article-title":"Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study","volume":"23","author":"Lanciano","year":"2005","journal-title":"J Clin Oncol"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2007.10.011","article-title":"Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g\/dL with erythropoietin vs above 10.0 g\/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer","volume":"108","author":"Thomas","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1200\/JCO.2013.51.4265","article-title":"Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study","volume":"32","author":"DiSilvestro","year":"2014","journal-title":"J Clin Oncol"},{"key":"R43-20260916","first-page":"401","article-title":"Hyperostosis and multifocal osteitis: a purely rheumatological subset of the SAPHO syndrome","volume":"8","author":"Trotta","year":"1990","journal-title":"Clin Exp Rheumatol"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"R45-20260916","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"Kunos","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R46-20260916","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R50-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"R51-20260916","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"R52-20260916","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2019.3857","article-title":"Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer","volume":"6","author":"Mayadev","year":"2020","journal-title":"JAMA Oncol"},{"key":"R53-20260916","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1002\/cncr.33136","article-title":"Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer","volume":"126","author":"Duska","year":"2020","journal-title":"Cancer"},{"key":"R54-20260916","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/ijgc-2019-001012","article-title":"Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"R55-20260916","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ijgc-2019-001135","article-title":"CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"R59-20260916","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"R60-20260916","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"R61-20260916","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"R62-20260916","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"R63-20260916","doi-asserted-by":"crossref","first-page":"910486","DOI":"10.3389\/fonc.2022.910486","article-title":"Efficacy and safety of pembrolizumab on cervical cancer: a systematic review and single-arm meta-analysis","volume":"12","author":"Qi","year":"2022","journal-title":"Front Oncol"},{"key":"R65-20260916","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:01:54Z","timestamp":1789556514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005413","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"2023-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}